Ironwood Pharmaceuticals Raises Full-Year 2026 Financial Guidance Driven by Continued LINZESS U.S. Net Sales Growth and Strong Third Quarter Financial…
IRONWOOD PHARMACEUTICALS INC (IRWD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Ironwood Pharmaceuticals Raises Full-Year 2026 Financial Guidance Driven by Continued LINZESS U.S. Net Sales Growth and Strong Third Quarter Financial Performance – Raises full-year 2026 LINZESS® (linaclotide) U.S. net sales guidance to $1.20 -
How this was made
The 30-second read
Why it matters
The guidance raise is the primary new fact, providing fresh quantitative expectations for revenue and EBITDA.
Market read
Guidance lift is likely to attract short‑term buying and may influence sector sentiment.
What to watch
Potential regulatory delays for apraglutide and reliance on AbbVie partnership could temper upside.
Ironwood Pharmaceuticals Raises Full-Year 2026 Financial Guidance Driven by Continued LINZESS U.S. Net Sales Growth and Strong Third Quarter Financial Performance
Third-quarter revenue, GAAP net income, non-GAAP net income and adjusted EBITDA all increased from the prior-year quarter, while the company raised 2026 guidance for LINZESS U.S. net sales, total revenue and adjusted EBITDA.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Q3 2026 total revenueGAAP | $133M | – | – |
| Q3 2026 collaboration revenue associated with Ironwood's share of LINZESS U.S. net profitsGAAP | $129.9M | – | 8.6% increase |
| Q3 2026 royalties and other revenueGAAP | $3.1M | – | – |
| Q3 2026 total costs and expensesGAAP | $39.9M | – | – |
| Q3 2026 research and development expensesGAAP | $28.3M | – | – |
| Q3 2026 selling, general and administrative expensesGAAP | $11.6M | – | – |
| Q3 2026 restructuring expensesGAAP | $— | – | – |
| Q3 2026 income from operationsGAAP | $93.13M | – | – |
| Q3 2026 interest expense and other financing costsGAAP | −$6.20M | – | – |
| Q3 2026 interest and investment incomeGAAP | $619K | – | – |
| Q3 2026 other incomeGAAP | $41K | – | – |
| Q3 2026 income before income taxesGAAP | $87.60M | – | – |
| Q3 2026 income tax expenseGAAP | $27.8M | – | – |
| Q3 2026 GAAP net incomeGAAP | $59.8M | – | – |
| Q3 2026 GAAP net income per share, basicGAAP | $0.36 per share | – | – |
| Q3 2026 GAAP net income per share, dilutedGAAP | $0.36 per share | – | – |
| Q3 2026 non-GAAP net incomenon-GAAP | $60M | – | – |
| Q3 2026 non-GAAP net income per share, basicnon-GAAP | $0.36 per share | – | – |
| Q3 2026 non-GAAP net income per share, dilutednon-GAAP | $0.36 per share | – | – |
| Q3 2026 adjusted EBITDAnon-GAAP | $97.9M | – | – |
| Q3 2026 LINZESS commercial marginother | 79.8% | – | – |
| Q3 2026 LINZESS prescription demandother | 63.4 million LINZESS capsules | – | 4.9% increase |
| Q3 2026 LINZESS U.S. net salesother | $324.9M | – | 3.2% increase |
| Q3 2026 total net profit on sales of LINZESSother | $255.9M | – | 9.8% increase |
| Nine months ended September 30, 2026 total revenuesGAAP | $352.6M | – | – |
| Nine months ended September 30, 2026 total costs and expensesGAAP | $107.6M | – | – |
| Nine months ended September 30, 2026 income from operationsGAAP | $245.0M | – | – |
| Nine months ended September 30, 2026 GAAP net incomeGAAP | $151.9M | – | – |
| Nine months ended September 30, 2026 GAAP net income per share, basicGAAP | $0.92 | – | – |
| Nine months ended September 30, 2026 GAAP net income per share, dilutedGAAP | $0.91 | – | – |
| Nine months ended September 30, 2026 non-GAAP net incomenon-GAAP | $152.5M | – | – |
| Nine months ended September 30, 2026 non-GAAP net income per share, basicnon-GAAP | $0.92 | – | – |
| Nine months ended September 30, 2026 non-GAAP net income per share, dilutednon-GAAP | $0.91 | – | – |
| Nine months ended September 30, 2026 adjusted EBITDAnon-GAAP | $257.6M | – | – |
| Nine months ended September 30, 2026 LINZESS U.S. net salesother | $879.8M | – | – |
| Nine months ended September 30, 2026 LINZESS commercial marginother | 78% | – | – |
| Nine months ended September 30, 2026 total net profit on sales of LINZESSother | $675.2M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| U.S. LINZESS brand collaborationQ3 2026 LINZESS U.S. net sales growth year-over-year was driven by 4.9% demand growth and low single-digit net price decline due to unfavorable gross-to-net rebate reserves in the third quarter of 2026 relative to 2025. | $324.9 million in LINZESS U.S. net sales | – | 3.2% increase |
| Ironwood U.S. collaborative arrangements revenueIronwood and AbbVie share equally in U.S. brand collaboration profits. | $129.9M | – | 8.6% increase |
| Royalties and other revenueRoyalties and other revenue. | $3.1M | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Full-year 2026 updated guidance (November 2026) outlook
- Revenue$485 - $510 million
- NoteU.S. LINZESS Net Sales: $1.20 - $1.25 billion, driven by improved net price and mid-single digit percentage demand growth
- NoteAdjusted EBITDA: >$350 million
- NoteFor purposes of this guidance, Ironwood has assumed that it will not incur material expenses related to business development activities in 2026.
What drove it
- LINZESS prescription demand increased 4.9% compared to the third quarter of 2025.
- LINZESS U.S. net sales increased 3.2% compared to the third quarter of 2025.
- LINZESS commercial margin was 79.8% in the third quarter of 2026, compared to 75.9% in the third quarter of 2025.
- Total net profit for the LINZESS U.S. brand collaboration increased 9.8% compared to the third quarter of 2025.
- The planned activation of more than 100 STARS-2 sites in 22 countries is on track.
Concerns
- LINZESS U.S. net sales growth included a low single-digit net price decline due to unfavorable gross-to-net rebate reserves in the third quarter of 2026 relative to 2025.
- Research and development expenses were $28.3 million in the third quarter of 2026, compared to $22.5 million in the third quarter of 2025.
- The STARS-2 trial is ongoing, and Ironwood’s plans to file for regulatory approval in 2029 are subject to its results.
- The revolving credit facility had an outstanding principal balance of $325.0 million as of September 30, 2026.
What to watch
- LINZESS U.S. net sales performance against updated full-year guidance of $1.20 - $1.25 billion.
- The balance of demand growth, improved net price and gross-to-net rebate reserves in LINZESS performance.
- Execution of the STARS-2 confirmatory Phase 3 trial, including U.S. and global site activation.
- Cash generation, revolving-credit repayments and remaining borrowing capacity.
- The leadership transition effective January 1, 2027, when Tammi Gaskins is to become Chief Executive Officer and Tom McCourt is to retire from his current role and remain a Board member.
Balance sheet and cash flow
- Cash and cash equivalents were $86.4 million at the end of the third quarter of 2026, compared to $215.5 million at the end of 2025.
- Cash and cash equivalents were $86,376 (in thousands) as of September 30, 2026, compared to $215,456 (in thousands) as of December 31, 2025.
- Ironwood generated $130.8 million in cash from operations in the third quarter of 2026, compared to $47.6 million in cash from operations in the third quarter of 2025.
- Ironwood repaid $60.0 million on the revolving credit facility during the third quarter of 2026, reducing the outstanding principal balance to $325.0 million as of September 30, 2026.
- Remaining borrowing capacity available under the revolving credit facility was $225.0 million.
- Accounts receivable was $132.7 million as of September 30, 2026, primarily related to the third quarter 2026 collaboration revenues.
- Total assets were $290,592 (in thousands) as of September 30, 2026, compared to $396,901 (in thousands) as of December 31, 2025.
- Total liabilities were $387,785 (in thousands) as of September 30, 2026, compared to $658,736 (in thousands) as of December 31, 2025.
- Total stockholders’ deficit was $(97,193) (in thousands) as of September 30, 2026, compared to $(261,835) (in thousands) as of December 31, 2025.
Analysis
Ironwood reported a stronger third quarter, with total revenue of $133.0 million versus $122.1 million in the third quarter of 2025. The principal contributor was $129.9 million of LINZESS-related collaboration revenue, up 8.6%, while LINZESS U.S. net sales reported by AbbVie rose 3.2% to $324.9 million. Prescription demand grew 4.9% to 63.4 million LINZESS capsules, while the company attributed net-sales growth to demand growth and a low single-digit net-price decline caused by unfavorable gross-to-net rebate reserves.
Profitability improved across reported measures. Total costs and expenses were $39.9 million, below $46.6 million in the prior-year quarter, despite R&D expense increasing to $28.3 million from $22.5 million. GAAP net income was $59.8 million, compared with $40.1 million, and adjusted EBITDA reached a record $97.9 million, compared with $81.8 million. LINZESS commercial margin was 79.8%, compared with 75.9%, and total net profit for the U.S. LINZESS brand collaboration increased 9.8% to $255.9 million.
The nine-month figures show the same operating pattern. Total revenues were $352,587 (in thousands), GAAP net income was $151,902 (in thousands), and adjusted EBITDA was $257,638 (in thousands), compared with $248,442 (in thousands), $26,293 (in thousands), and $127,170 (in thousands), respectively, in the prior-year period. Nine-month LINZESS U.S. net sales were $879,753 (in thousands), exceeding full-year 2025 U.S. net sales according to the company.
Cash generation was substantial in the quarter, with $130.8 million in cash from operations versus $47.6 million a year earlier. Ironwood repaid $60.0 million on its revolving credit facility, leaving a $325.0 million outstanding principal balance and $225.0 million of remaining borrowing capacity. Cash and cash equivalents were $86.4 million at quarter end, compared with $215.5 million at the end of 2025, while accounts receivable were $132.7 million.
Management raised full-year 2026 guidance to $1.20 - $1.25 billion for LINZESS U.S. net sales, $485 - $510 million for total revenue, and greater than $350 million for adjusted EBITDA. The development focus remains the ongoing STARS-2 confirmatory Phase 3 trial of apraglutide. Ironwood stated that planned activation of more than 100 sites in 22 countries is on track and that it plans to file for regulatory approval in 2029, subject to trial results.
Management, verbatim
Ironwood delivered a third consecutive strong quarter as we continue focused execution of our three strategic priorities: maximize LINZESS, advance apraglutide and deliver sustained profits and cash flows. We believe LINZESS is on its way to returning to blockbuster status for 2026 with year-to-date U.S. net sales already surpassing total 2025 U.S. net sales, primarily driven by improved net price and mid-single-digit prescription demand growth. This gives us confidence to increase full-year 2026 financial guidance for the second consecutive quarter.
Tom McCourt, Chief Executive Officer
In addition to driving strong financial performance, we are ramping up the STARS-2 confirmatory Phase 3 trial of apraglutide in people living with short bowel syndrome with intestinal failure. As we continue to add trial sites in the U.S., all of the planned clinical trial applications have been submitted to international health authorities and are now under review or already approved. Our current focus is on activating sites as quickly as possible to accelerate the trial as we work toward the goal of bringing apraglutide to patients.
Tom McCourt, Chief Executive Officer
Not in the filing
stated, not guessed- Free cash flow was not reported.
- Share repurchases were not reported.
- Dividends were not reported.
- GAAP gross margin was not reported.
- GAAP operating-expense guidance was not provided.
- Tax-rate guidance was not provided.
- GAAP net-income guidance was not provided.
- Prior-quarter comparisons were not reported for the presented operating metrics.
- A separate previous earnings release or prior outlook document was not provided for formal actual-versus-prior-guidance comparison.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was checked against the filing text, and a metric whose value, prior period and change do not add up is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
The filing is an SEC Form 8‑K Item 2.02 reporting Q3 2026 results and updated guidance for 2026.
Ticker impact
Ironwood Pharmaceuticals raised its full-year 2026 LINZESS U.S. net sales guidance to $1.20‑$1.25 B and total revenue guidance to $485‑$510 M, citing Q3 performance.
upward pressure as the market prices in higher revenue and EBITDA expectations
The raised guidance reflects a >35% YoY sales increase and record adjusted EBITDA, which typically drives buying interest in biotech stocks.
Market effects
Boosts outlook for GI‑focused biotech sector and may lift peers with similar drug pipelines.
Positive for US biotech listings on Nasdaq.
Limited to investors tracking specialty pharma earnings and guidance trends.
Counterpoint
If LINZESS pricing pressure persists, the raised guidance may be overly optimistic.
Key entities
- CompanyIronwood Pharmaceuticals
Biotech firm developing LINZESS and apraglutide.
- PartnerAbbVie Inc.
U.S. partner sharing LINZESS profits.
